Paresh Dandona is a Distinguished Professor of Medicine and chief of the Division of Endocrinology, Diabetes and Metabolism, at the University at Buffalo, The State University of New York. He is also the founder and director of the Diabetes Endocrinology Center of Western New York in Buffalo. Previously, he served as director of Diabetes and Metabolism at the Royal Free Hospital School of Medicine at the University of London, England, for 14 years. One of the world's leading experts in the treatment of diabetes and vascular disease, Dr. Dandona is a Rhodes Scholar from India, trained at the University of Oxford and the University of London.
The Diabetes Endocrinology Center of Western New York probably has the finest standards of diabetic care anywhere: it is 16 years since the last chronic diabetic foot ulcer, gangrene or amputation was observed, while it is 12 years since the last patient had diabetic end stage renal failure. Dr Dandona received the Valor Award of the American Diabetes Association for his contributions to the standards of care in diabetes and the establishment of a network of diabetes care in Western New York.
He received the Pharmacia-Pfizer/Endocrine Society Award for the discovery of the anti-inflammatory effect of insulin. This discovery has been extended into potential cardio-protective and neuro-protective effects of insulin in acute myocardial infarction and stroke. Trials are under way to translate these concepts into clinical practice. His work on obesity, oxidative stress and inflammation, and the pro-inflammatory effects of macronutrients (foods) is now recognized globally. His team is currently busy investigating potential anti-inflammatory foods. The third major discovery by his team is that of low testosterone concentrations in males with Type 2 Diabetes and obesity. His team has demonstrated that this is the most common cause of male hypogonadism and potentially infertility. He is currently leading pioneering trials on the benefits of testosterone replacement and other treatments in such patients. These studies show that hypogonadal patients are more insulin resistant and that testosterone treatment reverses this defect.
Dr. Dandona has published more than 540 papers in peer-reviewed medical journals, and has presented keynote lectures on diabetes and insulin resistance at many national and international conferences. He is the founder editor of Metabolic Syndrome and Related Disorders, and is or has been on the editorial boards of the Journal of Clinical Endocrinology and Metabolism, Diabetes Care, Current Diabetes Reviews and Journal of Diabetes.